Mengis Capital Management Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,045 shares of the company’s stock after selling 600 shares during the period. Johnson & Johnson comprises 2.5% of Mengis Capital Management Inc.’s investment portfolio, making the stock its 9th largest position. Mengis Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently made changes to their positions in the company. Harding Loevner LP purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Shine Investment Advisory Services Inc. purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $177,000. Finally, Lenox Wealth Management Inc. increased its stake in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares during the period. 65.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE JNJ) opened at $129.53 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 1 year low of $114.23 and a 1 year high of $148.32. The firm has a market capitalization of $347,980.00, a P/E ratio of 332.13, a P/E/G ratio of 2.33 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the previous year, the company posted $1.58 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.08 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio is presently 861.54%.
A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective on the stock in a research report on Wednesday, December 20th. BMO Capital Markets lifted their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Finally, BTIG Research reiterated a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $146.16.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.